Galactin, NASH

Galactin, NASH

Title: Study Evaluating the Efficacy and Safety of Belapectin (GR-MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis

Associated condition: NASH

Status: Currently enrolling

Brief summary: This is a seamless, adaptive, two-stage, Phase 2b/3, randomized, double-blind, multicenter, parallel-groups, placebo-controlled study. Subjects will be assigned to one of three treatment arms for each of the two stages: subjects in the first experimental arm will receive belapectin 2 mg/kg lean body mass (LBM) administered intravenously (IV) every other week for 78 weeks in Phase 2b, then switch to the optimal dose in Phase 3; in another experimental arm, subjects will receive belapectin 4 mg/kg LBM IV every other week for 78 weeks in Phase 2b then switch to the optimal dose in Phase 3; those in the placebo comparator group will receive IV placebo every other week for both Phase 2b and Phase 3.

Primary objectives: To evaluate the efficacy, tolerability, and safety of belapectin (GR-MD-02) for the prevention of esophageal varices in NASH cirrhosis.

Estimated length of study: 18 months, with a study start date of June 22, 2020 and an estimated end date of December 22, 2021

For more detailed information on this research trial, including eligibility and study design, please visit the clinical trial page at U.S. National Library of Medicine’s website. Note you can submit your information for consideration by submitting the contact form on this page.

Submit Your Information for Consideration

HIPAA COMPLIANT FORM

Title: Study Evaluating the Efficacy and Safety of Belapectin (GR-MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis

Associated condition: NASH

Status: Currently enrolling

Brief summary: This is a seamless, adaptive, two-stage, Phase 2b/3, randomized, double-blind, multicenter, parallel-groups, placebo-controlled study. Subjects will be assigned to one of three treatment arms for each of the two stages: subjects in the first experimental arm will receive belapectin 2 mg/kg lean body mass (LBM) administered intravenously (IV) every other week for 78 weeks in Phase 2b, then switch to the optimal dose in Phase 3; in another experimental arm, subjects will receive belapectin 4 mg/kg LBM IV every other week for 78 weeks in Phase 2b then switch to the optimal dose in Phase 3; those in the placebo comparator group will receive IV placebo every other week for both Phase 2b and Phase 3.

Primary objectives: To evaluate the efficacy, tolerability, and safety of belapectin (GR-MD-02) for the prevention of esophageal varices in NASH cirrhosis.

Estimated length of study: 18 months, with a study start date of June 22, 2020 and an estimated end date of December 22, 2021

For more detailed information on this research trial, including eligibility and study design, please visit the clinical trial page at U.S. National Library of Medicine’s website. Note you can submit your information for consideration by submitting the contact form on this page.

Submit Your Information for Consideration

The physicians at Digestive Healthcare of Georgia are closely monitoring the coronavirus (COVID-19) outbreak. In the interest of everyone’s health and safety we ask all patients and their guests who have a fever (100° or above), symptoms of a respiratory infection, or who may have traveled to a restricted country or may have been exposed to a person with known COVID-19, the flu or any other communicable disease to reschedule their appointments or procedures. You will not be charged for canceling/rescheduling your appointment. We will be following CDC and Georgia Department of Public Health’s recommendations for screening and management of patients. If you are at all concerned you may have a serious infectious disease, your best course of action is to seek care at your primary care physician’s office or local hospital’s emergency department.

We have implemented a telemedicine visit for our patients who are unable to be in the office for their appointment. Please call our office to schedule a telemedicine visit with your provider.